ReviewFrontiers in immunology2026
Targeting lineage-specific heterogeneity and hypovascular-fibrotic barriers may enable precision immunotherapy in pituitary neuroendocrine tumors.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical management of refractory pituitary neuroendocrine tumors (PitNETs) remains a formidable challenge due to pervasive resistance to traditional therapies. Current therapeutic failures appear closely associated with lineage-specific immune heterogeneity and the unique "hypovascular-fibrotic" physical barrier that hinders drug delivery. This review critically examines the biological determinants of therapeutic resistance in the tumor microenvironment (TME) to propose a comprehensive framework for precision immuno-oncology. We highlight how immune infiltration profiles and checkpoint expressions are strongly influenced by transcriptional lineages across PIT1-, TPIT-, and SF1-lineage tumors. We elucidate the "hypovascular-fibrotic" barrier, where low microvessel density and dense collagen deposition restrict therapeutic penetration. We also evaluate advanced strategies, including spatial multi-omics for precise patient stratification and focused ultrasound (FUS) for enhanced drug delivery. In the end, we outline potential combinatorial strategies integrating vascular normalization and metabolic reprogramming to synergize with immune checkpoint inhibitors. This mechanism-driven paradigm shift from empirical treatment to precision immuno-oncology may provide critical insights and novel therapeutic strategies for intractable PitNETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.